Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermaglós is a prominent brand of dermatological and skin-care products developed by Laboratorios Andrómaco, primarily marketed in Argentina and other Latin American regions. The flagship therapeutic formulation is an over-the-counter (OTC) topical cream or emulsion containing a combination of Vitamin A (retinol), Vitamin E (tocopherol), and Allantoin. It is indicated for the promotion of skin healing, the prevention and treatment of stretch marks (striae distensae), the management of minor burns and solar erythema, and the hydration of dry or irritated skin. Vitamin A facilitates skin regeneration by modulating gene expression through retinoic acid receptors, while Vitamin E provides antioxidant defense against free radicals, and Allantoin acts as a soothing agent that enhances the skin's moisture-binding capacity. The Dermaglós portfolio has expanded to include specialized lines for sun protection, facial aesthetics, and pediatric care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermaglós.